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Cochrane Collaborative Review Group on
Peripheral Vascular Diseases: Review AbstractsIntroduction
The following abstracts are part of an ongoing series
of articles produced by the Cochrane Collaborative
Review Group on Peripheral Vascular Diseases,
which is part of The Cochrane Collaboration. The
reviews are published in full on The Cochrane
Library, a quarterly electronic journal available on
CD-ROM and via the Internet. The electronic format
allows Cochrane reviews to accommodate new data
as they become available, making the library a
consistently up-to-date source of information over
time.
Certain abstracts appearing on The Cochrane Library
may be presented in a simpler, less scientific format
than the abstract presented here to permit greater
accessibility to the public. However, the substance of
both versions is the same. Cochrane reviews are
now indexed on MEDLINE.
If you are interested in conducting a Cochrane
review or contributing to the activities of the
Cochrane Collaborative Review Group on Peripheral
Vascular Diseases, please contact:
Professor FGR Fowkes
Cochrane Collaborative Review Group on Periph-
eral Vascular Diseases
Public Health Sciences
University of Edinburgh
Teviot Place
Edinburgh EH8 9AG
Tel.: þ44 (0) 131 650 3220
Fax.: þ44 (0) 131 650 6904
Any comments or criticisms on Cochrane reviews/
abstracts should be made through the comments/
criticisms facility on The Cochrane Library, or by
contacting the group at the above address.1078–5884/000475+ 03 $35.00/0  2006 Published by Elsevier Ltd.Abstracts
Abstract. Phlebotonics for venous insufficiency
M.J. Martinez, X. Bonfill, R.M. Moreno, E. Vargas,
D. Capella`
First published: The Cochrane Library Issue 3, 2005
Background
Chronic venous insufficiency (CVI) is a common
condition caused by inadequate blood flow through
the veins, usually in the lower limbs. It can result in
considerable discomfort with symptoms such as
pain, itchiness and tiredness in the legs. Sufferers
may also experience swelling and ulcers. Phlebotonics
are a class of drugs that are often used to treat CVI.
Objectives
To assess the efficacy of oral or topical phlebotonics in
CVI.
Search strategy
The Cochrane Peripheral Vascular Diseases Group
searched their trials register (last searched April
2005) and the Cochrane Central Register of Controlled
Trials (CENTRAL) in The Cochrane Library (last
searched Issue 2, 2005). The review authors searched
MEDLINE (January 1966 to April 2005), EMBASE
(January 1980 to April 2005) and reference lists of
articles. The review authors also contacted pharma-
ceutical companies.
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Randomised, double blind, placebo-controlled trials
(RCTs) assessing the efficacy of rutosides, hidrosmine,
diosmine, calcium dobesilate, chromocarbe, centella
asiatica, disodium flavodate, french maritime pine
bark extract, grape seed extract and aminaftone in
CVI patients at any stage of the disease.
Data collection and analysis
Two review authors independently extracted data and
assessed trial quality. The effects of treatment were
estimated by relative risk (RR) or by standardised
mean differences (SMD) by applying a random-effects
statistical model. Sensitivity analyses were also
performed.
Main results
Fifty-nine RCTs of oral phlebotonics were included,
but only 44 trials involving 4413 participants con-
tained quantifiable data for the efficacy analysis: 23
of rutosides, ten of hidrosmine and diosmine, six of
calcium dobesilate, two of centella asiatica, one of
french maritime pine bark extract, one of aminaftone,
and one of grape seed extract. No studies evaluating
topical phlebotonics, chromocarbe, naftazone or diso-
dium flavodate fulfilled the inclusion criteria.
Outcomes included oedema, venous ulcers, trophic
disorders, subjective symptoms (pain, cramps, restless
legs, itching, heaviness, swelling and paraesthesias),
global assessment measures and side effects. The
results of many variables were heterogeneous. Phle-
botonics showed some global benefit (i.e. oedema
reduction) (RR 0.72; 95% confidence interval 0.65 to
0.81). The benefit for the remaining CVI signs and
symptoms must be evaluated by phlebotonic group.
There were no quantifiable data on quality of life.
Authors’ conclusions
There is not enough evidence to support the efficacy
of phlebotonics for chronic venous insufficiency.
There is a suggestion of some efficacy of phlebotonics
on oedema but this is of uncertain clinical relevance.
Due to the limitations of current evidence, there
is a need for further randomised, controlled clinical
trials with greater attention paid to methodological
quality.Eur J Vasc Endovasc Surg Vol 32, November 2006Abstract. Anticoagulants versus non-steroidal anti-
inflammatories or placebo for treatment of venous
thromboembolism.
D.K. Cundiff, J. Manyemba, J.C. Pezzullo
First published: The Cochrane Library Issue 1, 2006
Background
Venous thromboembolism (VTE) is the term given to
any thromboembolic event occurring in the venous
system. The current treatment recommended for
VTE is anticoagulation. The aim of this review is to
summarize results from randomized controlled trials
(RCTs) for the effectiveness of anticoagulants (hepa-
rins, including low molecular weight heparins and
vitamin K antagonists) in the treatment of VTE,
compared to non-steroidal anti-inflammatory drugs
(NSAIDs) or placebo.
Objectives
To examine the randomized controlled evidence for
the effectiveness and safety of anticoagulant treatment
compared to NSAIDs or placebo in patients with VTE
on the incidence of fatal and non-fatal pulmonary em-
boli (PE) and the recurrence or extension of deep vein
thrombosis (DVT).
Search strategy
The Cochrane Peripheral Vascular Diseases Group
searched their trials register (last searched 26 July
2005) and the Cochrane Central Register of Controlled
Trials (CENTRAL) in The Cochrane Library (last
searched Issue 3, 2005). In addition, DKC also
searched reference lists and contacted pharmaceutical
companies and experts in the field.
Selection criteria
All randomized trials of anticoagulants versus
NSAIDs or placebo in the initial treatment of VTE
(DVT or PE or both).
Data collection and analysis
DKC and JM independently assessed trial quality and
extracted data. JCP (biostatistician) analyzed the de-
sign elements and feasibility of a future randomized
controlled trial to determine definitively efficacy and
safety of anticoagulants in VTE treatment.
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Two RCTs were included. Data were not pooled
because of heterogeneity between the studies. The
two RCTs were too small to determine any difference
in mortality, occurrence of pulmonary emboli, or
progression or return of DVT between patients
treated with anticoagulation and those receiving no
anticoagulation.
Authors’ conclusions
The limited evidence from RCTs of anticoagulants
versus NSAIDs or placebo is inconclusive regarding
the efficacy and safety of anticoagulants in VTE treat-
ment. The use of anticoagulants is widely accepted in
clinical practice, so a further RCTcomparing anticoag-
ulants to placebo could not ethically be carried out.
Abstract. Surgery versus non-surgical treatment for
femoral pseudoaneurysms
P.V. Tisi, M.J. Callam
First published: The Cochrane Library Issue 1, 2006
Background
Femoral pseudoaneurysms may complicate up to 8%
of vascular interventional procedures. Small pseudoa-
neurysms can spontaneously clot, while others need
definitive treatment. Surgery is considered the gold-
standard treatment, although is not without risk in
patients with severe cardiovascular disease. Less
invasive treatment options, such as Duplex ultrasound-
guided compression and percutaneous thrombin
injection are available, however, evidence of their
efficacy is limited.
Objectives
To assess the effects of different treatments for femoral
pseudoaneurysms resulting from endovascular proce-
dures, specifically assessing less invasive treatment
options such as ultrasound-guided compression or
percutaneous thrombin injection.
Search strategy
The Cochrane Peripheral Vascular Diseases Group
searched their trials register (last searched 12 October
2005) and the Cochrane Central Register of ControlledTrials (CENTRAL) in The Cochrane Library (last
searched Issue 3, 2005). Additional searches were
also made of bibliographies of papers found through
these searches and by handsearching relevant
journals.
Selection criteria
Randomised controlled trials comparing two treat-
ments for femoral pseudoaneurysms following vascu-
lar interventional procedures were considered for
inclusion in the review.
Data collection and analysis
Two studies were included in the analysis: ultrasound-
guided application of a mechanical device (FemoStop)
versus blind application; ultrasound-guided compres-
sion versus percutaneous thrombin injection. Data
were extracted independently by both authors.
Main results
Mechanical compression with a FemoStop was effec-
tive in achieving thrombosis of the pseudoaneurysm
although ultrasound-guided application of this failed
to confer any benefit (relative risk (RR) 1.07; 95% con-
fidence intervals (CI) 0.75 to 1.53, P¼ 0.7).
Percutaneous thrombin injection was more effec-
tive than ultrasound-guided compression in achiev-
ing thrombosis of a pseudoaneurysm (RR 7.50; 95%
CI 2.06 to 27.25, P¼ 0.002 at 24 hours after treatment;
RR 2.50; 95% CI 1.35 to 4.65, P¼ 0.004 at 48 hours after
treatment). There was no statistically significant dif-
ference in the length of hospital stay between the
two groups and no complications were reported.
Authors’ conclusions
The limited evidence base appears to support the use
of thrombin injection as an effective treatment for
femoral pseudoaneurysm. A pragmatic approach
may be to use ultrasound-guided compression as
first-line treatment, reserving thrombin injection for
those in whom the procedure fails.
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